title: Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
abstract: We compared combination therapy with low-dose aspirin plus ticlopidine to therapy with aspirin alone or ticlopidine alone in patients suffering transient ischemic attack or cerebral infarction. In 17, 24, and 23 patients, respectively, 300 mg/day aspirin, 200 mg/day ticlopidine, and 81 mg/day aspirin plus 100 mg/day ticlopidine were administered orally. Aspirin alone markedly inhibited platelet aggregation induced by arachidonic acid, partially inhibited platelet aggregation induced by adenosine diphosphate, and did not inhibit platelet aggregation induced by platelet activating factor. Ticlopidine alone inhibited platelet aggregation induced by adenosine diphosphate and platelet activating factor, but did not inhibit platelet aggregation induced by arachidonic acid. Combination therapy with aspirin plus ticlopidine markedly inhibited platelet aggregation induced by all three agonists. Plasma concentrations of beta-thromboglobulin and platelet factor 4 remained unchanged by aspirin alone, were slightly reduced by ticlopidine alone, and were markedly reduced by aspirin plus ticlopidine. Plasma concentration of thromboxane B2 was reduced by aspirin alone or with ticlopidine, but not by ticlopidine alone. The level of 6-ketoprostaglandin F1 alpha was reduced only by aspirin alone. Bleeding time was significantly prolonged by aspirin alone and by ticlopidine alone, although the greatest prolongation was produced by aspirin plus ticlopidine. Our results indicate that the combination of aspirin plus ticlopidine is a potent antiplatelet strategy, although the clinical importance of the changes observed need to be determined by a properly designed and controlled prospective study.
authors.affiliation: Department of Neurology, Tokyo Women's Medical College, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Uchiyama
authors.forename: R
authors.initials: R
authors.lastname: Sone
authors.forename: T
authors.initials: T
authors.lastname: Nagayama
authors.forename: Y
authors.initials: Y
authors.lastname: Shibagaki
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Maruyama
authors.forename: K
authors.initials: K
authors.lastname: Kusakabe
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy*; D002470:Cell Survival / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013988:Ticlopidine / Q000009:adverse effects / Q000627:therapeutic use*; D001620:beta-Thromboglobulin / Q000032:analysis
chemical_list: D010975:Platelet Aggregation Inhibitors; D001620:beta-Thromboglobulin; D015121:6-Ketoprostaglandin F1 alpha; D013988:Ticlopidine; D001241:Aspirin